{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:54:15Z","timestamp":1782996855387,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,12,5]],"date-time":"2012-12-05T00:00:00Z","timestamp":1354665600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s40262-012-0023-8","type":"journal-article","created":{"date-parts":[[2012,12,17]],"date-time":"2012-12-17T20:38:56Z","timestamp":1355776736000},"page":"125-137","source":"Crossref","is-referenced-by-count":13,"title":["A Population Pharmacokinetic and Pharmacodynamic Study of a Peripheral \u03ba-Opioid Receptor Agonist CR665 and Oxycodone"],"prefix":"10.1007","volume":"52","author":[{"given":"Anne E.","family":"Olesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Staahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherron","family":"Kell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert Y.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Arendt-Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asbj\u00f8rn M.","family":"Drewes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,5]]},"reference":[{"issue":"3","key":"23_CR1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1055\/s-2005-857991","volume":"67","author":"HH Konig","year":"2005","unstructured":"Konig HH, Bernert S, Angermeyer MC. Health status of the German population: results of a representative survey using the EuroQol questionnaire. Gesundheitswesen. 2005;67(3):173\u201382.","journal-title":"Gesundheitswesen"},{"issue":"1","key":"23_CR2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1526-4637.2008.00495.x","volume":"10","author":"TJ Bell","year":"2009","unstructured":"Bell TJ, Panchal SJ, Miaskowski C, et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009;10(1):35\u201342.","journal-title":"Pain Med"},{"issue":"8","key":"23_CR3","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/nm908","volume":"9","author":"C Stein","year":"2003","unstructured":"Stein C, Schafer M, Machelska H. Attacking pain at its source: new perspectives on opioids. Nat Med. 2003;9(8):1003\u20138.","journal-title":"Nat Med"},{"issue":"8","key":"23_CR4","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/sj.bjp.0705763","volume":"141","author":"PJ Riviere","year":"2004","unstructured":"Riviere PJ. Peripheral kappa-opioid agonists for visceral pain. Br J Pharmacol. 2004;141(8):1331\u20134.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"23_CR5","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0022-3565(24)37421-X","volume":"285","author":"MB Burton","year":"1998","unstructured":"Burton MB, Gebhart GF. Effects of kappa-opioid receptor agonists on responses to colorectal distension in rats with and without acute colonic inflammation. J Pharmacol Exp Ther. 1998;285(2):707\u201315.","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"23_CR6","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/00000542-200106000-00018","volume":"94","author":"W Binder","year":"2001","unstructured":"Binder W, Machelska H, Mousa S, et al. Analgesic and antiinflammatory effects of two novel kappa-opioid peptides. Anesthesiology. 2001;94(6):1034\u201344.","journal-title":"Anesthesiology"},{"issue":"1","key":"23_CR7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejphar.2008.01.011","volume":"583","author":"TW Vanderah","year":"2008","unstructured":"Vanderah TW, Largent-Milnes T, Lai J, et al. Novel D-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral kappa-opioid receptors. Eur J Pharmacol. 2008;583(1):62\u201372.","journal-title":"Eur J Pharmacol"},{"key":"23_CR8","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/ALN.0b013e3181af6356","volume":"111","author":"L Arendt-Nielsen","year":"2009","unstructured":"Arendt-Nielsen L, Olesen AE, Staahl C, et al. Analgesic efficacy of peripheral kappa opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective effect on visceral pain. Anesthesiology. 2009;111:616\u201324.","journal-title":"Anesthesiology"},{"issue":"5","key":"23_CR9","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/0091270008314465","volume":"48","author":"C Staahl","year":"2008","unstructured":"Staahl C, Upton R, Foster DJ, et al. Pharmacokinetic-pharmacodynamic modeling of morphine and oxycodone concentrations and analgesic effect in a multimodal experimental pain model. J Clin Pharmacol. 2008;48(5):619\u201331.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"23_CR10","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1742-7843.2010.00649.x","volume":"108","author":"T Andresen","year":"2011","unstructured":"Andresen T, Upton RN, Foster DJ, et al. Pharmacokinetic\/pharmacodynamic relationships of transdermal buprenorphine and fentanyl in experimental human pain models. Basic Clin Pharmacol Toxicol. 2011;108(4):274\u201384.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"12","key":"23_CR11","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2165\/11536610-000000000-00000","volume":"49","author":"AE Olesen","year":"2010","unstructured":"Olesen AE, Upton R, Foster DJ, et al. A pharmacokinetic and pharmacodynamic study of oral oxycodone in a human experimental pain model of hyperalgesia. Clin Pharmacokinet. 2010;49(12):817\u201327.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"23_CR12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1213\/ane.0b013e3181753288","volume":"107","author":"SL Shafer","year":"2008","unstructured":"Shafer SL, Struys MM. Mixed effect modeling in analgesia trials. Anesth Analg. 2008;107(1):9\u201310.","journal-title":"Anesth Analg"},{"issue":"3","key":"23_CR13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10928-005-9002-0","volume":"33","author":"C Csajka","year":"2006","unstructured":"Csajka C, Verotta D. Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J Pharmacokinet Pharmacodyn. 2006;33(3):227\u201379.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"9","key":"23_CR14","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3109\/03639049509069806","volume":"21","author":"SE Rosenbaum","year":"1995","unstructured":"Rosenbaum SE, Carter AA, Dudley MN. Population pharmacokinetics: fundamentals, methods and applications. Drug Dev Ind Pharm. 1995;21(9):1115\u201341.","journal-title":"Drug Dev Ind Pharm"},{"issue":"1","key":"23_CR15","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.pbb.2005.12.013","volume":"83","author":"JR Holtman","year":"2006","unstructured":"Holtman JR, Wala EP. Characterization of the antinociceptive effect of oxycodone in male and female rats. Pharmacol Biochem Behav. 2006;83(1):100\u20138.","journal-title":"Pharmacol Biochem Behav"},{"issue":"3","key":"23_CR16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pain.2007.03.022","volume":"132","author":"CK Nielsen","year":"2007","unstructured":"Nielsen CK, Ross FB, Lotfipour S, et al. Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain. 2007;132(3):289\u2013300.","journal-title":"Pain"},{"issue":"1\u20133","key":"23_CR17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejphar.2006.02.002","volume":"535","author":"C Nozaki","year":"2006","unstructured":"Nozaki C, Saitoh A, Kamei J. Characterization of the antinociceptive effects of oxycodone in diabetic mice. Eur J Pharmacol. 2006;535(1\u20133):145\u201351.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"23_CR18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0304-3959(97)00093-6","volume":"73","author":"FB Ross","year":"1997","unstructured":"Ross FB, Smith MT. The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain. 1997;73(2):151\u20137.","journal-title":"Pain"},{"issue":"16","key":"23_CR19","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.3748\/wjg.v12.i16.2477","volume":"12","author":"AM Drewes","year":"2006","unstructured":"Drewes AM, Gregersen H. Multimodal pain stimulation of the gastrointestinal tract. World J Gastroenterol. 2006;12(16):2477\u201386.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"23_CR20","doi-asserted-by":"crossref","first-page":"G95","DOI":"10.1152\/ajpgi.00496.2001","volume":"283","author":"AM Drewes","year":"2002","unstructured":"Drewes AM, Schipper KP, Dimcevski G, et al. Multimodal assessment of pain in the esophagus: a new experimental model. Am J Physiol Gastrointest Liver Physiol. 2002;283(1):G95\u2013103.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"3","key":"23_CR21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit: a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241\u201357.","journal-title":"Comput Methods Programs Biomed"},{"issue":"2","key":"23_CR22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN): a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75(2):85\u201394.","journal-title":"Comput Methods Programs Biomed"},{"issue":"5","key":"23_CR23","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","volume":"34","author":"RM Savic","year":"2007","unstructured":"Savic RM, Jonker DM, Kerbusch T, et al. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007;34(5):711\u201326.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"23_CR24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/0091270006293758","volume":"47","author":"L Fang","year":"2007","unstructured":"Fang L, Holford NH, Hinkle G, et al. Population pharmacokinetics of humanized monoclonal antibody HuCC49deltaCH2 and murine antibody CC49 in colorectal cancer patients. J Clin Pharmacol. 2007;47(2):227\u201337.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"23_CR25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1011555016423","volume":"28","author":"Y Yano","year":"2001","unstructured":"Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic\/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn. 2001;28(2):171\u201392.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"23_CR26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-199630050-00001","volume":"30","author":"NH Holford","year":"1996","unstructured":"Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet. 1996;30(5):329\u201332.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"23_CR27","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.clpt.2006.01.009","volume":"79","author":"B Lalovic","year":"2006","unstructured":"Lalovic B, Kharasch E, Hoffer C, et al. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther. 2006;79(5):461\u201379.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"23_CR28","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1046\/j.1365-2125.1996.00481.x","volume":"42","author":"JW Mandema","year":"1996","unstructured":"Mandema JW, Kaiko RF, Oshlack B, et al. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. Br J Clin Pharmacol. 1996;42(6):747\u201356.","journal-title":"Br J Clin Pharmacol"},{"key":"23_CR29","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/01621459.1995.10476572","volume":"90","author":"R Kass","year":"1995","unstructured":"Kass R, Raftery A. Bayes factors. J Am Stat Assoc. 1995;90:773\u201395.","journal-title":"J Am Stat Assoc"},{"issue":"5","key":"23_CR30","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.jpainsymman.2005.01.012","volume":"29","author":"J Lotsch","year":"2005","unstructured":"Lotsch J. Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manage. 2005;29(5):S90\u2013103.","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"23_CR31","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1152\/jn.2000.83.4.2209","volume":"83","author":"N Ozaki","year":"2000","unstructured":"Ozaki N, Sengupta JN, Gebhart GF. Differential effects of mu-, delta-, and kappa-opioid receptor agonists on mechanosensitive gastric vagal afferent fibers in the rat. J Neurophysiol. 2000;83(4):2209\u201316.","journal-title":"J Neurophysiol"},{"issue":"5","key":"23_CR32","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1177\/0091270008315318","volume":"48","author":"JS Barrett","year":"2008","unstructured":"Barrett JS, Fossler MJ, Cadieu KD, et al. Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings. J Clin Pharmacol. 2008;48(5):632\u201349.","journal-title":"J Clin Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-012-0023-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-012-0023-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-012-0023-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T20:12:39Z","timestamp":1745439159000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-012-0023-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,5]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["23"],"URL":"https:\/\/doi.org\/10.1007\/s40262-012-0023-8","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,5]]}}}